Drug Price Information and Cost-Consciousness of Physicians: Results of a Survey of Belgian General Practitioners

  • D. de Graeve
  • G. Carrin
Part of the Health Systems Research book series (HEALTH)


The Belgian Ministry of Public Health distributes an Independent Drug Formulary (IDF) on a 2-yearly basis. This formulary (called the Gecommentarieerd Geneesmiddelenrepertorium) is edited by a group of prominent experts in pharmacology, brought together by the Belgian Centre for Pharmacotherapeutic Information. It contains scientific information about all drugs marketed in Belgium; it also mentions the brand name, composition, package form, prices per package and reimbursement category. [The NHI reimburses drugs according to their reimbursement category. Drugs of category (a) are totally reimbursed. For pensioners, widows, orphans and invalids, the NHI reimburses 85%, 50% and 40% for drugs of categories (b), (c) and (cs) respectively; for other insured persons, the reimbursement percentages are respectively 75%, 50% and 40%. Drugs of category (d) are not reimbursed.] Daily drug costs and comparisons between those costs for similar therapies are not provided, however. There is also a brief comparison between the relative medical effectiveness of the drugs in similar therapeutic categories; price comparisons are absent, however. This formulary is sent, free of charge, to all Belgian physicians and pharmacists. Students in the last 2 years of their graduate studies also receive a copy.


Posit Editing Medex 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Avorn J, Soumerai S (1983) Improving drug therapy decisions through educational outreach.Google Scholar
  2. A randomized controlled trial of academically based “detailing”. N Engl J Med 308:1457–1463Google Scholar
  3. Babington M, Robinson L, Monson R (1983) Effect of written information on physicians’ knowledge of drug prices. South Econ J 76(3):328–331Google Scholar
  4. Kesenne J, Feltesse P (1988) De Uitgaven van de Ziekteverzekering voor Werknemers van 1945 tot 1986. Dossier 16, Landsbond van Christelijke Mutualiteiten, Brussel, p 96Google Scholar
  5. Lilja J (1976) How physician’s choose their drugs. Soc Sci Med 10:363–365PubMedCrossRefGoogle Scholar
  6. Lowy DR, Lowy L, Warner RS (1972) A survey of physicians’ awareness of drug costs. J Med Educ 47:349–351PubMedGoogle Scholar
  7. Manning P, Lee P, Clintworth W, Denson T, Oppenheimer P, Gilman N (1986) Changing prescribing practices through individual continuing education. J Am Med Assoc 256(2):230–232CrossRefGoogle Scholar
  8. Oppenheim GL, Erickson SH, Ashworth C (1981) The family physician’s knowledge of the cost of prescribed drugs. J Fam Pract 12(6):1027–1030PubMedGoogle Scholar
  9. Schroeder SA, Kenders K, Cooper J, Piemme T (1973) Use of laboratory tests and pharmaceuticals. Variation among physicians and effect of cost audit and subsequent use. J Am Med Assoc 225(8):969–973CrossRefGoogle Scholar
  10. Soumerai SB, Avorn J (1984) Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Milbank Mem Fund Q/Health Soc 62(3):447–474CrossRefGoogle Scholar
  11. Zelnio R (1982) Physician’s use of the guide to prescription drug costs: an exploration. Drug Intell Clin Pharm 16:874–875PubMedGoogle Scholar
  12. Zelnio RN, Gagnon JP (1979) The effects of price information on physician prescribing patterns — a literature review. Drug Intell Clin Pharm 13:156–159PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • D. de Graeve
  • G. Carrin

There are no affiliations available

Personalised recommendations